Agenus’ Post

BMS-986442 (AGEN1777), a novel TIGIT/CD96 bispecific antibody, demonstrates superior monotherapy and combination activity versus conventional anti-TIGIT antibodies in preclinical models View our oral #AACR2024 presentation at: https://lnkd.in/eqzP6-JF #Immunotherapy #CancerResearch #TIGIT #CD96

We are thrilled to share that our President and CEO, Dr Anthony G Johnson, along with our Chief Business Officer, Sean A. MacDonald, will be attending three prestigious investor, partnering and healthcare industry conferences: Bloom Burton & Co. Healthcare Investor Conference hosted by Bloom Burton & Co. LSX World Congress organized by LSX - partnering for Life Science eXecutives BioEquity Europe organized by teams from BioCentury Inc. and EBD Group What’s in the spotlight? This is a unique opportunity to gain insights into our latest advancements in precision #immunotherapy. Our leaders will be showcasing the promising clinical development prospects of our pipeline, which is dedicated exclusively to GPCRs in #immunooncology. They will be focusing on our key drug candidates: DT-7012, an anti-CCR8 Treg-depleting monoclonal antibody in preclinical development DT-9045, a small molecule PAR2 receptor antagonist, also in preclinical development DT-9081, currently in Phase I clinical trials, this small molecule targets the EP4 receptor Don’t miss this chance to meet our passionate and success-driven leaders face-to-face. They are eager to discuss strategies that will further solidify our position as the leading #GPCR company in immuno-oncology. Stay tuned for official updates and highlights from each event and reach out if you would like to schedule a meeting. For more information, please follow the link in comments. #drugdevelopment #precisionmedicine

AlzeCure publishes its interim report for, January – September 2023 Read AlzeCure's interim report for the period January – September 2023 “The third quarter of 2023 was positive and eventful for AlzeCure Pharma. During the period, we presented new, positive, detailed proof-of-mechanism (POM) results from our Phase II clinical study with ACD440 for the treatment of peripheral neuropathic pain. In addition, we published new preclinical data for our clinical drug candidate NeuroRestore ACD856 supporting potential neuroprotective and disease-modifying effects in Alzheimer’s and other neurodegenerative diseases. We also published new preclinical results demonstrating the antidepressant effects of our NeuroRestore compounds. It is gratifying to see that we are keeping up the pace as we continue to deliver and generate new data that strengthen our position, while also paving the way for new opportunities.” Martin Jönsson, CEO Read the press release here: https://lnkd.in/dgCU2qsM The interim report for July – September 2023 is also available on the company's website: https://lnkd.in/eVUtWqNq #alzecure #redeye #alzheimerfonden #avanza #nordnet #edisongroup #seb #swedbank #nordea #aktiespararna #privataaffarer #vatorsecurities #finwire #penser #erikpenserbank

Register to attend the Oxford Global Biomarkers US 2023 conference, Oct. 12-13, in San Diego, CA. Hear from pharma, biotech, and academic organizations working to identify biomarkers suitable for use with a variety of therapeutics and learn how technological advances are paving the way for precision medicine development. Meet with us at the event to discuss methods that can help you identify biomarkers that enhance patient stratification and improve clinical trial outcomes. https://hubs.ly/Q023lgQN0 #Biomarkers #ClinicalTrials #SpatialBiology #ImageAnalysis #ImmunoOncology #Immunotherapy #ImmuneProfiling #TumorMicroenvironment #CancerResearch

ONE DAY LEFT to register for this informative lunch meeting to learn more about "REGULATORY AND DESIGN TRENDS IN CLINICAL TRIALS". If you are in the #SanFranciso #BayArea please join us. #clinicaltrialdesign #trialoptimization #regulatorystatistics

We are pleased to share good news from AIM ImmunoTech (NYSE American: AIM), one of our featured companies at B2i Digital. AIM was granted two new US patents for their drug Ampligen! What does this mean? Put simply - it strengthens and extends AIM’s rights to use Ampligen for treating cancers and chronic fatigue/ME until 2039-2040. Key takeaways: - One patent covers unique combos of Ampligen with other drugs for pancreatic, kidney, colon cancers, etc., where it could improve outcomes. - The second patent is for precision methods to treat ME/CFS with Ampligen tailored to specific patients, a significant development for this neglected disease. With sole rights extended, AIM can further develop these approaches with Ampligen, either alone or with partners through 2039-2040. Click here if you would like to watch a video of CEO Thomas Equels discussing the issuance of these two key patents. https://lnkd.in/dpuHBi-A Congratulations to the team at AIM ImmunoTech, including CEO Thomas Equels, COO Peter Rodino III, Chief Scientific & Medical Officer David Strayer, and CFO Robert Dickey! As a featured company, we at B2i Digital are proud to see your progress in pioneering new therapies. These new patents are outstanding achievements that bode well for the future. Keep up the great work! Featured Company Profile: https://lnkd.in/eTNN4849 #LongCOVID #chronicfatigue #clinicaltrials #biotech #immunotherapy #Ampligen #MECFS #patents

Alzheimer’s Drug Discovery Researchers/Scientists An opportunity to learn about Patient Stratification What is patient stratification and how could it revolutionize drug discovery? Register for our next webinar to find out! On Wednesday 26th July (4pm BST), we'll be running a webinar on "Using the power of iPSCs for patient stratification" hosted by our Chief Scientific Officer, Ashley Barnes, and our Head of Sales and Marketing, Duncan Borthwick. You can expect Ashley and Duncan to cover: 1. The value of iPSC-based cell models in capturing population diversity 2. Overcoming the current limitations of in vitro disease models 3. The importance of quality and consistency of iPSC disease models, including the current regulatory landscape 4. Utilizing high-throughput cell assays for drug discovery 5. How patient stratification can de-risk and accelerate drug discovery, including identifying key biomarkers that predict drug efficacy Register here: https://hubs.la/Q01Xh1qK0 Wed, July 26, 4:00 PM - 5:00 PM (BST) | 4pm BST | 5pm CEST | 10am CDT | 11am EDT | 8am PDT | We look forward to having you attend the event! #iPSCs #BetterHumanDiseaseModels #DrugDiscovery #AlzheimersDisease #PatientStratification #alzheimersresearch #Humancells #cellculture

Struggling with the “Double-blinded placebo-controlled randomized controlled clinical trial for patients with Anal Intraepithelial Neoplasia (AIN),” Frantz Viral Therapeutics, a joint venture between Georgetown University Medical Center and Frantz Medical Group, faced numerous challenges while dealing with the trial phases. Moving ahead, they reached out to us with their concern over the ongoing challenges and sought help through Jeeva Clinical Trials Inc.'s eclinical solutions to accelerate their research. Learn how we accepted the challenges and, through our efficient and innovative solutions, assisted them in fulfilling their objectives from this case study: https://hubs.la/Q02gg2dj0 #RCT #clinicaltrials #AIN #healthtech #casestudy #randomizedclinicaltrial

Although it's a hypothesis related to IKZF2 degradation, there's an intriguing aspect. PVTX-405, developed by SK Life Science Labs (formerly known as Proteovant), functions by degrading IKZF2 in Tregs, which in turn diminishes the Tregs' ability to utilize IL-2 via the CD25 receptor. This reduction in IL-2 consumption by Tregs effectively increases the availability of IL-2 for effector T cells. Thus, PVTX-405 indirectly promotes the activation and proliferation of effector T cells by making more IL-2 available rather than being used up by Tregs. By allowing IL-2 to interact not only with the beta and gamma receptors but also with the alpha receptor, PVTX-405 could harness a broader range of IL-2's immunostimulatory effects. This approach might result in more robust activation of effector T cells than IL-2 variants designed to interact only with beta and gamma receptors. 📊https://abit.ly/nnvngx #AACR24 💡Novartis recently discontinued the development of its IKZF2 degrader, DKY709, while Plexium Therapeutics is currently advancing their IKZF2 degrader, PLX-4545, through Phase 1 clinical trials.